N
Google TrendPOSICIONES DE ATLÉTICO DE MADRID CONTRA MANCHESTER UNITED (5000+) — Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:posiciones de atlético de madrid contra manchester united5000+devils vs red wings2000+lioness season 35000+luis díaz200+halle berry child custody hearing200+lamine yamal5000+thélyson orélien500+abdulrahman alfozan500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "FDA Approves Lyrfigtu for" (30 stories)

Top Headline Story

FDA Approves Lirafugratinib for Treating Cholangiocarcinoma Caused by FGFR2 Mutations
Lead StoryMemorial Sloan Kettering Cancer Centergeneral
Oct 1

FDA Approves Lirafugratinib for Treating Cholangiocarcinoma Caused by FGFR2 Mutations

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPZFBVb24zb1V1T1YzMl82LV9vb2dYYVdRYlo5bXNxQUJOZHJhalhoU0NkVEN3aE1QUFRaYzNJU0VtR09KZzE2SXVKdFNFQjE5WUp0ODl5cGdSRmdZLVFWUnQ2Nkx0d1podWtfSVZtb2lKZ3pucDhXaFU2U0FZRWM3Slh4eEQ1bFVKXzdZN2dCNlJhRWxFV1ZBVFAzUG9RSzNaQ2xXaW1SbTJxSjZ1ZWk0aG5R?oc=5" target="_blank">FDA Approves Lirafugratinib for Treating Cholangiocarcinoma Caused by FGFR2 Mutations</a>  <font color="#6f6f6f">Memorial Sloan Kettering Cancer Center</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+19m ago

posiciones de atlético de madrid contra manchester united

Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League

Filter stories
2000+19m ago

devils vs red wings

Devils at Red Wings projected lineups

Filter stories
5000+19m ago

lioness season 3

Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger

Filter stories
200+29m ago

luis díaz

Max Eberl knows Luis Díaz will start scoring again for Bayern Munich

Filter stories

Search Results for "FDA Approves Lyrfigtu for"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
FDA Approves Lyrfigtu for FGFR2-Rearranged Cholangiocarcinoma
The Clinical Trial Vanguardgeneral

FDA Approves Lyrfigtu for FGFR2-Rearranged Cholangiocarcinoma

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQWTExVXcteTJ0TTRSWnN1U1FWRklJM2dxUzNZa3Y0clpHY3ZLODVoNS1zUmU0X0FfUXpxYVRva2tLWElNb3k3ZjRMcDN3S2xmTFMySVpGek9LZmlyMjZwUTg4QWtSSmhDa0Z4cHVxQ3RvczVfVVE5eU50Q1lNazZiaU9rMldvQ0s4TVFKeGQwOGJGODkwMElfN1p6NVAwRElOSlJCcTNSN28?oc=5" target="_blank">FDA Approves Lyrfigtu for FGFR2-Rearranged Cholangiocarcinoma</a>  <font color="#6f6f6f">The Clinical Trial Vanguard</font>

Read Full StoryMore like this
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
OncLivegeneral

FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOVjFMYjdkUmNGc0JUcEw1b1JDMWU3a2g1QzI0TjFyRDFzbGs4YWY2R2JZNTNUUTQzbFBwOUNwWlhxZkxOM1J4cmdFYlV1a1d6VDhOMnpUTF9QbmZIMFhwcWNzVVBPRGFpOVljMGc5YVBnVWQtVjB0eE0tWUtvaUVlMzZCWGhOMGpkcUJnQXNrTGZPenZzY1ZncGU0QjBndjRNYkx3cFRzc3FzbjIxS1VhQm84amN6RW5fZDVWYk5B?oc=5" target="_blank">FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Elevar wins FDA nod for bile duct cancer drug Lyrfigtu, a first for a Korean firm
Fierce Pharmageneral

Elevar wins FDA nod for bile duct cancer drug Lyrfigtu, a first for a Korean firm

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNG9ZNWFUakhnNTJTQmhsMkM5Y1lDWkJLNTdvNXhpVXpLOTMtVWwteWdSbzhLWTlzcGZyOGU5OXlaM3ZUMEJBRkoyWWduZF9tMlBIS3JLeFV0cHFXajlIY1RrU2p5cHRsdHRJcU9fZEh2bFZFYTczY2lGeFVzR1RRN2JXVEY4S3JqSzV0SEFVOWJraGJxTTgwLXBCODQ2OU5IWTd3SGZRWEptMW8?oc=5" target="_blank">Elevar wins FDA nod for bile duct cancer drug Lyrfigtu, a first for a Korean firm</a>  <font color="#6f6f6f">Fierce Pharma</font>

Read Full StoryMore like this
Elevar Therapeutics Announces FDA Approval of Lyrfigtu
GlobeNewswireworld

Elevar Therapeutics Announces FDA Approval of Lyrfigtu

<a href="https://news.google.com/rss/articles/CBMi0wJBVV95cUxPRnZLbnFYaHFSa2VBT0tYeHZHelp6amI2X3FUY1pUbmlwcGxzR204TmFPamlUU1I3RVJlWlFEcjFad0xzVVg2UUk4ekpHeFg4MkRnd2VZOFpvX2xMX05JY2V1SjFmSGw0NEFjeGF5NUNlZHFNOFBoZlpRVDdlSWk4ZzRVZV95bmUzMFMwSTBnb2N0NlRFZHpGMmJtYUs0VE5iQVNwRHpvdi13T3ZEUFVLS2xjNEN6VTRaZGhWOVRQZzAyWUNjQmlfNEktbkFXT2tCVnlSMnE5MEZxc1l0X1FKSk9ZYklMU09QOVpodDVJWVpWWUs3eDBOb0lwX1lmRHc0TFhuTEdhNzFVTkdvdzQwR2dRNDlUVU1ZZ2JqVWNuOFhYN3JoRGtUYlVfZ2FjbXFjS1U1T0FoUnNUVFY4bnJuamU0VHItdXU2NUtGXzgyVU54XzA?oc=5" target="_blank">Elevar Therapeutics Announces FDA Approval of Lyrfigtu</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
FDA Approves Lyrfigtu for Previously Treated FGFR2-Positive Cholangiocarcinoma
Cure Todaygeneral

FDA Approves Lyrfigtu for Previously Treated FGFR2-Positive Cholangiocarcinoma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOR0kyQk9RYUFPZl9KakZWTlVUbkZYNUZ1dERoOExld0s2VXJXcU51T29JVDNEQllISmM5MjdjVEdrQjg5bU9qOTlweTFZYnEwM3Z6RmpOOVZpQmx5NzEwa2VRaG53azNSOUM4VGk0Ty1XQTdUS3RJQkdrdXdmYW5MSlItbW03LWhQN0dKaWZqTlktamxkNFpNdmJTbUtHdThPblFXcjhwSnNMWGNWdkE?oc=5" target="_blank">FDA Approves Lyrfigtu for Previously Treated FGFR2-Positive Cholangiocarcinoma</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
FDA Approves New Option for Previously Treated Bile Duct Cancer
MedPage Todaygeneral

FDA Approves New Option for Previously Treated Bile Duct Cancer

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFBaMzAyVUhIeFViQTIyVVEzTWxpM3M0MmJzRlY3Mll5cUh3Qk1ZT2FnT1lRT2YzVldvZDcxRXNLeEh6RTNMdDdYUlFfQ2t1NnhGaHZMMkVCSjN6cVZONmVMdm4wYjBmcklnX0J2NUNSUHktZlgtTEE?oc=5" target="_blank">FDA Approves New Option for Previously Treated Bile Duct Cancer</a>  <font color="#6f6f6f">MedPage Today</font>

Read Full StoryMore like this
HLB's liver cancer drug push gains momentum after first FDA approval
The Korea Heraldtech

HLB's liver cancer drug push gains momentum after first FDA approval

<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTFBpOWthMlI3Wk1XMFlRLWNXbFhETkgyWEhrMFR1d1FYZEhfcm1TVWl4LTZ4OFhPTG91cnFaVURNNFdfNFQ0SkVTQnp3YWN0T2U5c0FyaVlWNA?oc=5" target="_blank">HLB's liver cancer drug push gains momentum after first FDA approval</a>  <font color="#6f6f6f">The Korea Herald</font>

Read Full StoryMore like this
HLB's Lyrfigtu wins FDA approval for FGFR2-altered bile duct cancer
Korea Biomedical Reviewgeneral

HLB's Lyrfigtu wins FDA approval for FGFR2-altered bile duct cancer

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9IeUx1WVZhWUtPTl9LQnFMTlRlV2h4c2hDZ1doUWszdWJ6dHZNOERPOWo2TVRpQkNCOVhwUW9RTHg4MWxBV0pyV2pKaGRfZTY0dXpEVGxWS3F3c0FaUkVZOFViaEs1ckJVWXVXTXdn0gFyQVVfeXFMUDZhR3llOHlCMS1lVVQwTFdKbHA5LUhRSW1jWlFqaEhQT09tb2RCT2toTGJ0dG85YW4zcmFHdHFUeERZRnBRMzJjS0RhMUtYVkQtczByTjZOb1lLUDFjZUhXZEtwRHppal83RXJkY3RzRDhR?oc=5" target="_blank">HLB's Lyrfigtu wins FDA approval for FGFR2-altered bile duct cancer</a>  <font color="#6f6f6f">Korea Biomedical Review</font>

Read Full StoryMore like this
FDA Approves Elevar Therapeutics Lyrfigtu as First-Ever Targeted FGFR2 Inhibitor for Advanced Bile Duct Cancer Care
geneonline.comgeneral

FDA Approves Elevar Therapeutics Lyrfigtu as First-Ever Targeted FGFR2 Inhibitor for Advanced Bile Duct Cancer Care

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOU25YSUx0SlhiRHJDbUJ6Qk56MEE1QjJQRWJ5UW9oRzVtdGdJTkNGYVcyNUVNaUw0MmJUZGxNZTNMZzBCVXdZOEN2NFlkUFhfRHRsQzhkRTdVbl9OSTdHOFdLWlJkSkNFMTFYZktFMWsxWDJqeEJZQkVpbVp4NjJRanpiVmw2MnJBaFEtR2lDbk5KWlRzaWhTX2MtWUFkaXZiWVF6Q0NhelhBRVBXUUZrLTFFakdUYktvbWFFUi1GczZuaW16UFAyaC1hd2wxSDcyVzNuZFRmYWd0UTQ?oc=5" target="_blank">FDA Approves Elevar Therapeutics Lyrfigtu as First-Ever Targeted FGFR2 Inhibitor for Advanced Bile Duct Cancer Care</a>  <font color="#6f6f6f">geneonline.com</font>

Read Full StoryMore like this
Elevar wins FDA approval for FGFR2 inhibitor Lyrfigtu
AllScigeneral

Elevar wins FDA approval for FGFR2 inhibitor Lyrfigtu

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxPZ0dDN0NjMWw5dW9sbVdMUXN2YnY1cnlFNmNkdXRyRV8wMTh4ZE1VdDgwczdDTnRyS0hfOVAyNEk3SlhndkVEUHFzOEJvZzU5UWh5WTdZeS12emtzYzMxV1BXMDB1UlJELXluT2Z2cUpDYVM5TDBPN2xZdktzaDktWlBaUXRXdw?oc=5" target="_blank">Elevar wins FDA approval for FGFR2 inhibitor Lyrfigtu</a>  <font color="#6f6f6f">AllSci</font>

Read Full StoryMore like this
Elevar wins first FDA approval with second-line drug for bile duct cancer
Endpoints Newsgeneral

Elevar wins first FDA approval with second-line drug for bile duct cancer

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNUWFpOXQ2ZHE3c3hZX1A5U09zdXJmWUlXaHZXcWQ1dU50cHktdGVZcEpLVWt3ZzZnQW82bnNNeFZYUnRXVVpmQXY3TXFtWElZbE5BNGJLWERlM2pGbVlqaE4wZ2N5OTZ5Xy00ZXpmTGxZRGpBUEkwY0RJZm9TMVliY2hlTjctcjNNN29zVDFnbllHMkZHbmZCeg?oc=5" target="_blank">Elevar wins first FDA approval with second-line drug for bile duct cancer</a>  <font color="#6f6f6f">Endpoints News</font>

Read Full StoryMore like this
FGFR2 inhibitor Lyrfigtu wins FDA approval for bile duct cancer
BioWorld Newsgeneral

FGFR2 inhibitor Lyrfigtu wins FDA approval for bile duct cancer

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQQWo1dEd5TU53bFVRVWNSZU1zWDY1SW9yMkFyY1M4S1lTWlBNdWZtaEdUY2JzdmgxRmhoNkpLaWw2dU9qbmh3ZFhURW0xQ2xkSUV1UHd0YVU3R2ZmMTc0OGRzTlUxZFdVQlZWcWJyVlpmTHg3UGxmLXpaZFhfajFTWFZWMkRJX1NWbW9ubl82YUxSVXZ0RXpHMHVvYkwtZ1NmS2R3NDlEWQ?oc=5" target="_blank">FGFR2 inhibitor Lyrfigtu wins FDA approval for bile duct cancer</a>  <font color="#6f6f6f">BioWorld News</font>

Read Full StoryMore like this
HLB's FDA-Approved Acquired Bile Duct Drug
조선일보general

HLB's FDA-Approved Acquired Bile Duct Drug

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPa0JydzdPY0JydGJtV2tfNGp6bm1zVEl6clJVWldPeFFRaV8yQTYyTHJHUDVkUE9SRjN4YzhQd2hSVEtIcU9iMkZOQUJHbEllNW0wZ2Z5QWs2aEU5dDBuV2dMd1JjdnZNY25yZVNnQ3h0YVBXcmFlZ0s4Tmt5ME4wZGJ1ZkY5ck9k?oc=5" target="_blank">HLB's FDA-Approved Acquired Bile Duct Drug</a>  <font color="#6f6f6f">조선일보</font>

Read Full StoryMore like this
FDA approves Lyrfigtu as second-line treatment option for certain bile duct cancer patients
Indian Pharma Posttech

FDA approves Lyrfigtu as second-line treatment option for certain bile duct cancer patients

<a href="https://news.google.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?oc=5" target="_blank">FDA approves Lyrfigtu as second-line treatment option for certain bile duct cancer patients</a>  <font color="#6f6f6f">Indian Pharma Post</font>

Read Full StoryMore like this
HLB Pharmaceutical Hits Upper Limit for Second Day as Lyrfigtu's U.S. Approval Fuels Group-Wide Rally
BigGo Financegeneral

HLB Pharmaceutical Hits Upper Limit for Second Day as Lyrfigtu's U.S. Approval Fuels Group-Wide Rally

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE9tSkVPNkF3T0VCdG5yWUprUTlMSUVUUkNTdDFRY1VCdVpHQS1KSFRPbEVtWUREWFAwWkVlMHp3WjRzR0ZjQXh1d3RpZm10X1NZSWhwbFFwaUNQQ0RPRXJDTVd0ODl5ZDRySG4xMElTcjZjMG5IaWc?oc=5" target="_blank">HLB Pharmaceutical Hits Upper Limit for Second Day as Lyrfigtu's U.S. Approval Fuels Group-Wide Rally</a>  <font color="#6f6f6f">BigGo Finance</font>

Read Full StoryMore like this
Once-Daily Lirafugratinib Wins FDA Approval for…
Inkltech

Once-Daily Lirafugratinib Wins FDA Approval for…

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPbEw0Q0lCUUFhX0FNWUNsWnFINDlhSGtfY2VMc2h5c3hRajRBa1dlQUlCZURma2pVMzNTZ19DX0ZLaF9vLVFSa1lZbFdiTkdzYlFpYXRleDk2eVluZjdKUVJGbzlWeW9oRHp1ZFRKS3UzSjBRWGRXdTZJSWpjNlhJdWMyOXVqRU5sQWtYcHQyb2JReFJ4X1F4WGVjNmhCMGVOa0ZWbDBKRks1QVBrS1d5QUcyUmpWczRJMkJMbHFiTU5kbk4wczYwVUFsY2pCSzg3R0JkOFg2QzliQQ?oc=5" target="_blank">Once-Daily Lirafugratinib Wins FDA Approval for…</a>  <font color="#6f6f6f">Inkl</font>

Read Full StoryMore like this
FDA approval of HLB bile duct cancer drug sends Korea group stocks soaring - CHOSUNBIZ
Chosunbizmarkets

FDA approval of HLB bile duct cancer drug sends Korea group stocks soaring - CHOSUNBIZ

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxNSGNUdXhuYlI0Vk5rRkJ5bTlwdVg4Ui03WlFTQ2Z1Z1dKTGN1YzhXVnBBMm5raEZzb0NGZXdlYzU2LWRpaFVTdktMU0FoNE0yaTBMMGx4LXBRUGx4Q0pXNGt4emtBOFFFYVVKQ0RYM29TTExtRXY1aVc4TGpXdFBnedIBlAFBVV95cUxPT3FpaEluUXJKczlOalhORng3Yk5JUEpjRHdEUF84WE9hd0tPR1lNRWRINm5KZkE4LTdlOGlBVDdkREZvRlowY3F1YWRmZDl5aGFiU2lDM003cUlrXzZIYlVMNFpFM1N1SlQ1NWxiYnd6Zi1ucHhxanNVWjJDM1h6OTVIYTJqd3RScmdEai1pNkxTSWlM?oc=5" target="_blank">FDA approval of HLB bile duct cancer drug sends Korea group stocks soaring - CHOSUNBIZ</a>  <font color="#6f6f6f">Chosunbiz</font>

Read Full StoryMore like this
HLB wins FDA nod for bile duct cancer drug, revives Korea biotech push - CHOSUNBIZ
Chosunbiztech

HLB wins FDA nod for bile duct cancer drug, revives Korea biotech push - CHOSUNBIZ

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQX05IZElGek5LalRBQ3Jsbm1YZ0lsU29PQWZBUXJ6OVlSVVlXcUgybUNsamdSbklUTU5kdVg0dkJZSFF0MFhGd240bUt0a0ZhcV9HZGx0eldmTFVwa3NFTWRXVUxLMl9LTGw2ZFIzUmhENWM0TDgtR2tIdUFqU2d3Y9IBlAFBVV95cUxQTXB2RWlEYjZpV3VWSC05U19Nam5WUlN4TFhENVIwSHpteHdlN01lYmhDcWhWUHAyWV9VNFBZT0txd2lqQUUtMnRzYVZ6WFRWdmNVZFFJMnpxT0JUOGdkQkZvVEJTYWNJalRHR0V4emZ3bjVWU000STN2RHBFZ2dOZkdZVElmTFJndnBWUGFRZGZpdXE3?oc=5" target="_blank">HLB wins FDA nod for bile duct cancer drug, revives Korea biotech push - CHOSUNBIZ</a>  <font color="#6f6f6f">Chosunbiz</font>

Read Full StoryMore like this
FDA nears decision as HLB plans US launch of bile duct cancer drug Lyrfigtu
Chosunbizworld

FDA nears decision as HLB plans US launch of bile duct cancer drug Lyrfigtu

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxNZVFBeUl3aG9ZZnBUX0dYYmdiQjlCbGhpQm1LRVJNR2NTMy1yZnd6UlNUUGd5X0xFcnFXNFRqbm9HbDJMUkVyVVMxSmlvSXNpM01vTkx0VWxiV0RCZTdmNTRpSjFLYmViQlJOLWhBOXgwdVVsVnp2ajA2eGtnNDJGTg?oc=5" target="_blank">FDA nears decision as HLB plans US launch of bile duct cancer drug Lyrfigtu</a>  <font color="#6f6f6f">Chosunbiz</font>

Read Full StoryMore like this
HLB wins FDA nod for Lyrfigtu, drives global push and declares second founding - CHOSUNBIZ
Chosunbizworld

HLB wins FDA nod for Lyrfigtu, drives global push and declares second founding - CHOSUNBIZ

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOQzd3bXlWWVg2akQ2eWl5U2RfUmxMS1VrekJzOHJMZXVBSU85NE1HSGhhc19xdUZPLUlJNzhqcGNrd1NOUnItQ181c3Z3Nk5VT1RUeVJwUGNvd3p1dnpaOGZFQXNkVFQ3RU1uT1c4TFkyWEdDNm53a01oLXZaV3JBS9IBlAFBVV95cUxPS3pkSndaQWdpQ1dCTTZZVTQ2dmJtaUEzd0hiaVRNcjlGSTFMOGNiUXBaa3JXZE9IbWwtY3NTZTh5TWpOcjUxZ3hBUmtyS0YyVVFWZ3NlYXNpcUQtTVVsd0FHRUIzaFpWMGlwSXZ0Um9xS2tPQV94SkRoUDF2YUgxNUtVOVBudjFBVlc4WFRWOWk3OXZ4?oc=5" target="_blank">HLB wins FDA nod for Lyrfigtu, drives global push and declares second founding - CHOSUNBIZ</a>  <font color="#6f6f6f">Chosunbiz</font>

Read Full StoryMore like this
HLB wins FDA nod for FGFR2 cholangiocarcinoma drug, targets Q4 US launch - CHOSUNBIZ
Chosunbizworld

HLB wins FDA nod for FGFR2 cholangiocarcinoma drug, targets Q4 US launch - CHOSUNBIZ

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxNb1pnMUgxeVU3LWhqZ2t2ajAzQVVGNXduZEVQcjJ4emZGMVRqbEJLMm4wTUxIOXZLS25qZjJNSzZGTmFWT2RRbzhZVU5BY2VXVjRrdEZ5eWJHc2ZvMEJVMFluT1hxc2k0eEFaMUpBTEZpUGFfX3BROC1ZekUwamxIV9IBlAFBVV95cUxPTzhob2FBWDFuMEY2Nml2SWZzZzVrdlNtdl9Bck11Q0NNQlhWbVBHajJOdmVMSUpGemRaS0xqQmh3eUdxN3BPUUpaNzVISWVoUExrWHF5andCZWdtZzZkd3pKbVJMaDR3bmxhTDFnTG9DSURqbFV1NVh5NWRYTkR2NnFsRjNDX1AxY1JQREJQNENNVDZ3?oc=5" target="_blank">HLB wins FDA nod for FGFR2 cholangiocarcinoma drug, targets Q4 US launch - CHOSUNBIZ</a>  <font color="#6f6f6f">Chosunbiz</font>

Read Full StoryMore like this
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
The ASCO Postworld

FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQNm80QkVPdVJWQXBSenQtR3BOcDRmTE5KRzlVOXBKZWZNSkVIanlkRWRnRFlnUkdvdkU4TTJIZV9OZ2tNOVNZRHkyS3hoLUNFem11QzYwU3U0WC1RZUNYOGdBYXRxS0M5MTl1Tm9jbm5WVjF0WjdBaFllMW9LYXN6dlAzUWZTWm1YZ3V6Nk9zUWFpbGVTSEpOd21ReHd2OVgxcy0zYnpsWi1VckVVWmJ1VlIyZjBJSWFWSFBiV1luOFZRdGp4SUJNcFFYTEZWQTRlTm14ZGlMc1ZvazJOcGViTW54ZFM1Y1pVN1k0?oc=5" target="_blank">FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
FDA Approves Lirafugratinib for FGFR2-Altered Cholangiocarcinoma
Targeted Oncologygeneral

FDA Approves Lirafugratinib for FGFR2-Altered Cholangiocarcinoma

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQem5OdlE1X2dhWE1KWktVekVPTHFCNUxTcnMxUElHYWY4VXhZRU9ydWpMaXRFU01QMG52dVoxUnN1cHpsMFpzdGRuZHIwZUFfQWpwOGx0bVRncjZRSno2WG9fSnp3bXlrSEhFS3A4S3RZb3QtWnBoTFdGd01Qa0FYZmZpY3VNZTdodENxeGk4REpXYVJ0Q1hBSg?oc=5" target="_blank">FDA Approves Lirafugratinib for FGFR2-Altered Cholangiocarcinoma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA Approves Lirafugratinib for Previously Treated FGFR2-Altered Cholangiocarcinoma
Pharmacy Timesgeneral

FDA Approves Lirafugratinib for Previously Treated FGFR2-Altered Cholangiocarcinoma

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOMEJwOFVkNEM1aTJFZjhvOWlLMlNuWUxLeHFPdXZDRWo0clJJVUMxZ3BiRmpBXzd2MDRfcnVnRDUtSXdtNFk1NFR1U1hQVmswSjZDYVBia01CUl9kbndnQl9xWUUwUFRXUUQyYUJoNXpTQ2N0eldHdHV4YWRZOXJYWEpKdVUzVF9KLTRwVUxybkNtN0lESVdCcHpQU2JuNlhJSGFaQjZ1VXVPSUs0WWFRNlhQUFJHRXJwS1E?oc=5" target="_blank">FDA Approves Lirafugratinib for Previously Treated FGFR2-Altered Cholangiocarcinoma</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Elevar Therapeutics Receives FDA Conditional Acceptance of LYRFIGTU as Brand Name for Lirafugratinib
GlobeNewswiregeneral

Elevar Therapeutics Receives FDA Conditional Acceptance of LYRFIGTU as Brand Name for Lirafugratinib

<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxNU0haTzFfeDlVU096SDlaUld4bjJtcHJNcGE4QTJtNXNQNXFqc3cyT1NYbzFGYWFGSFFQeGppVk50MEpMYWdGakIxOXF4YU41NGRZOFZlbnpYdC0tNWQ4VnZZVjQ3cnFpTGtMamN0QTU2OGFnMUZxTTFwcEZDdmlWaWZGRTVZVDUwS0Z2TWR4Tmo3MmZDYTBlRTl4RTBPdE16OS1TVWdoN0xldjYxM1lwdGlrRGU4VkV5XzF6UkRDblNPUzRsMmdLRUlGZDZDT0x5Y0RKaTJvMDJQV1FJU1lhdnZGend4bS1uYkZSNkFnM1ZjRFlweTU4NFVSSEJLXzdKNkE?oc=5" target="_blank">Elevar Therapeutics Receives FDA Conditional Acceptance of LYRFIGTU as Brand Name for Lirafugratinib</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
FDA Approves First Colon Cancer Indication for Roche’s Tecentriq
Genome Webgeneral

FDA Approves First Colon Cancer Indication for Roche’s Tecentriq

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOempoZ3BFV3p2OWpnUUQ2ZDZaVW5LdmFBaHFCUkZJT1psYVF4VUR1bHRScWtuQjVOU243RGI5MXZzdTRFZWZhWFpmVVFWZE1HNGlsSVBhRUhVSjh0dHpvTU1oZjJ6NGRMT0lJZlc2My1mcU1naUNsUEEzSEMxcDEtbWJDQTR3cXJqYUF6V09oeVZXUC1OeDNZVlJCWnI1LW1URkdNQWhfdmhucWZWNHpF?oc=5" target="_blank">FDA Approves First Colon Cancer Indication for Roche’s Tecentriq</a>  <font color="#6f6f6f">Genome Web</font>

Read Full StoryMore like this
FDA Roundup: Oncology Drug Approvals in 2026
Cancer Therapy Advisorworld

FDA Roundup: Oncology Drug Approvals in 2026

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOczFIZWVqV0xrU3BhMGJfUXdUZEMyalJUSWlJdGxROW1mU2dLbFhQYl8xUHVyclBjRHBNcktBa3ZhYTJMQkljY3RRX01BWkpaRC1oUWtrQmVTVzltYVFQUnBxeGhRYlNtRXJyZmljdzMtNE9HeVU4Vl9zRHplYnBFNmt1S1BrQQ?oc=5" target="_blank">FDA Roundup: Oncology Drug Approvals in 2026</a>  <font color="#6f6f6f">Cancer Therapy Advisor</font>

Read Full StoryMore like this
FDA Approves Lirafugratinib for FGFR2-Positive Cholangiocarcinoma - Innovative Oncology Network
Oncodailygeneral

FDA Approves Lirafugratinib for FGFR2-Positive Cholangiocarcinoma - Innovative Oncology Network

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE9nMm9YMGdoRWtwdmF1Z3hfNi1WNWJDVDNnUFlNMTl3UDZoeUJwMHpuTUN4X3laS041aEh0b1FzRE1iRktrS2w0R2hCYjhxeUtXOVV0TkNLOGtFMUtIVkdFV2pfc1FpUUhMUjNVYWZ2Z3pvZw?oc=5" target="_blank">FDA Approves Lirafugratinib for FGFR2-Positive Cholangiocarcinoma - Innovative Oncology Network</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
FDA Approves Lirafugratinib for Advanced Bile Duct Cancer
Labrootsgeneral

FDA Approves Lirafugratinib for Advanced Bile Duct Cancer

<a href="https://news.google.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?oc=5" target="_blank">FDA Approves Lirafugratinib for Advanced Bile Duct Cancer</a>  <font color="#6f6f6f">Labroots</font>

Read Full StoryMore like this
"FDA Approves Lyrfigtu for" — Live Google News Trends & Headlines